SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-021069
Filing Date
2024-05-07
Accepted
2024-05-07 16:02:30
Documents
81
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcrx-20240331.htm   iXBRL 10-Q 1293523
2 EX-31.1 bcrx-20240331xexx311.htm EX-31.1 9615
3 EX-31.2 bcrx-20240331xexx312.htm EX-31.2 9589
4 EX-32.1 bcrx-20240331xexx321.htm EX-32.1 4662
5 EX-32.2 bcrx-20240331xexx322.htm EX-32.2 4636
  Complete submission text file 0001628280-24-021069.txt   7414985

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20240331.xsd EX-101.SCH 59388
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcrx-20240331_cal.xml EX-101.CAL 62622
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20240331_def.xml EX-101.DEF 245960
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20240331_lab.xml EX-101.LAB 693809
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20240331_pre.xml EX-101.PRE 472475
84 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20240331_htm.xml XML 1029130
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 24921671
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)